Released Mar 18, 2024, after the close
10-Q filed Mar 18, 2024, 47 days after period end · 0001654954-24-003314
Q1 2024 · 10-Q
Revenue$2.38M$2.38M −43.8% vs Q1 2023−33.9% vs Q4 2023
Net Income-$270.72K-$270.72K N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.01-$0.01 no prior Q1 2023 on fileno prior Q4 2023 on file
Gross Profit$535,609−56.8%
Operating Income-$438,300N/M
Operating Cash Flow$725,945−17.1%
Free Cash Flowderived$725,125−16.4%
Margins · derived
Gross margin22.5%−6.8 pt vs Q1 2023
Operating margin-18.4%−26.2 pt vs Q1 2023
Net margin-11.4%−21.4 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $2.38M | $4.24M | $5.02M | $4.49M |
| Net Income | -$270.72K | $426.43K | $305.24K | $268.03K |
| EPS Diluted | -$0.01 | — | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR